A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.
Clinical trial NCT05670925 · UNKNOWN
Trial details
- NCT number
- NCT05670925
- Sponsor
- Fudan University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-01
- Primary completion
- 2023-09-01
- Enrollment
- 46
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.